You are here


Gilead wins reversal of US$2.54b hepatitis C drug patent verdict


A US federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record US$2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

The verdict had been the largest ever in a US...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to